Collaboration and co-operation Sample Clauses

Collaboration and co-operation. 3.1 The Parties shall co-operate in accordance with the terms of this Agreement in relation the Project.
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
Collaboration and co-operation. 3.1 The UK Government White Paper Integration and Innovation sets out legislative proposals to integrate provision of services to deliver better health and wellbeing for everyone using all of the resources of the NHS, local authorities and the voluntary sector. 3.2 In order to pursue the public service benefits which are the object of integration, the parties have decided to co-operate within the Focus of this agreement in relation to certain Services. 3.3 The parties shall collaborate in relation to Service Schedules agreed in accordance with clause 6 (Proposals and Services). 3.4 The parties shall, in relation to all matters concerning the Focus, have regard to: (a) the national Healthy Child Programme; (b) the One Stockport Borough Plan; (c) the Stockport Early Help Strategy; (d) the Start Well Strategy; (e) the Stockport One Health and Care Plan; (f) the Health Needs Assessment; (g) [GM Early Years Model – to be confirmed reference]; (h) [SEND reference Joint Commissioning Plan / Joint Strategic NA – to be confirmed if any additional references] (i) the 7 Outcomes for Children framework; (j) the need to reduce inequalities between people within the borough of Stockport with respect to the benefits available through the Services provided under this Agreement; and (k) Co-production values and behaviours. [To be confirmed by both parties that this is full list of relevant publications] 3.5 In addition, and as a separate objective to the public service objectives, the Council and Trust intend that in implementing this collaboration, the people of the borough of Stockport will further benefit from the local expenditure of public funds allocated to the local authority and NHS bodies within Stockport.
Sample 1Sample 2
Collaboration and co-operation. 3.1 The parties shall co-operate in relation to delivery of the Project in the manner set out in the Partner Involvement Summary at Schedule 1. 3.2 The Partners shall collaborate in relation to the matters set out in this agreement for the delivery, management, monitoring and funding of the Project. 3.3 Each Delivery Partner undertakes to Selnet and to the other Delivery Partners to perform the obligations set out in the Adherence Agreement relating to it as such Adherence Agreement may be varied during the Project Period in accordance with the terms of this agreement. 3.4 Without prejudice to the generality of the preceding sub-clauses: (a) each Delivery Partner agrees to the terms of Schedule 5 and (b) in the event of termination of this agreement (and/or an Adherence Agreement) in relation to a Delivery Partner the Delivery Partner shall during any notice period ensure continued provision of Services to beneficiaries of the Services by it and use all reasonable endeavours to collaborate with and any Future Delivery Partner (as defined in Schedule 5) to facilitate continued provision of Services to beneficiaries of the Services across the change of Delivery Partner.
Sample 1
Collaboration and co-operation. 3.1 1MM shall provide the 1MM Services and the Partner shall provide the Partner Services from the Commencement Date. 3.2 Each party shall in relation to the obligations allocated to it pursuant to this agreement: (a) perform such obligations in accordance with timeframes or milestones (if any) specified in the 1MM Services and/or the Partner Services (as applicable); (b) use reasonable care and skill in performing such obligations; (c) comply with good industry practice; (d) comply with all laws applicable to it; (e) perform such obligations without damaging the reputation or goodwill of the other party or any of its Intellectual Property Rights; (f) obtain and maintain consents, licences and permissions (statutory, regulatory, contractual or otherwise) that are necessary to enable it to comply with such obligations; and (g) if on the other party's premises, comply with that party's health and safety and site regulations made known to it. 3.3 Each party shall ensure that it uses employees or agents in performing its obligations pursuant to this agreement who are suitably qualified and experienced.
Sample 1
Collaboration and co-operation. 3.1 The parties shall co-operate in relation to delivery of the Project in the manner set out in the Partner Involvement Summary annexed to this agreement as Annexure 2. 3.2 The Partners shall collaborate in relation to the matters set out in this agreement for the delivery, management, monitoring and funding of the Project. 3.3 Each Delivery Partner undertakes to Selnet and to the other Delivery Partners to perform the obligations set out in the Adherence Agreement relating to it as such Adherence Agreement may be varied during the Project Period in accordance with the terms of this agreement.
Sample 1
Collaboration and co-operation 
Sample 1

Related to Collaboration and co-operation

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Development Services During the term of this Agreement, the Provider agrees to provide to or on behalf of the Port the professional services and related items described in Exhibit A (collectively, the “Development Services”) in accordance with the terms and conditions of this Agreement. The Provider specifically agrees to include at least one Port representative in any economic development negotiations or discussions in which the Provider is involved concerning (i) a port-related business prospect or (ii) a business transaction which will ultimately require Port involvement, financial or otherwise.

  • Professional Development Program (a) The parties agree to continue a Professional Development Program for the maintenance and development of the faculty members' professional competence and effectiveness. It is agreed that maintenance of currency of subject knowledge, the improvement of performance of faculty duties, and the maintenance and improvement of professional competence, including instructional skills, are the primary professional development activities of faculty members. (b) Information collected as part of this program shall be the sole property of the faculty member. This information or any judgments arising from this program shall not be used to determine non-renewal or termination of a faculty member's contract, suspension or dismissal of a faculty member, denial of advancement on the salary scale, nor affect any other administrative decisions pertaining to the promotion or employment status of the faculty member. (c) A joint advisory committee consisting of three regular faculty members who shall be elected by and are P.D. Committee Chairpersons and three administrators shall make recommendations for the operation, financing and management of the Professional Development Program.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Formation and Composition The Parties to this agreement will maintain a Joint Administration and Dispute Resolution Committee (JADRC) consisting of five (5) representatives of the employers and five (5) representatives of the Provincial Bargaining Council.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!